<?xml version="1.0" encoding="UTF-8"?>

<ResearchStudy xmlns="http://hl7.org/fhir">
  <id value="ExampleStudyRAAINBOW"/>
  <meta>
    <profile value="https://www.vision-zero-oncology.de/fhir/StructureDefinition/clinical-study"/>
  </meta>
  <text>
    <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: ResearchStudy</b><a name="ExampleStudyRAAINBOW"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource ResearchStudy &quot;ExampleStudyRAAINBOW&quot; </p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-clinical-study.html">Profile Clinical Study</a></p></div><p><b>identifier</b>: id: NCT03240627</p><p><b>title</b>: Double-blind, Vehicle-controlled, Randomised, Multi-centre Study to Evaluate the Efficacy and Safety of LH-8 Cutaneous Solution in Children and Adolescents With Moderate to Severe Scalp Alopecia Areata.</p><p><b>status</b>: completed</p><p><b>primaryPurposeType</b>: Treatment <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-research-study-prim-purp-type.html">ResearchStudyPrimaryPurposeType</a>#treatment)</span></p><p><b>phase</b>: Phase 2/Phase 3 <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-research-study-phase.html">ResearchStudyPhase</a>#phase-2-phase-3)</span></p><p><b>category</b>: Interventional Study <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-v3-nciThesaurus.html">NCI Thesaurus</a>#C98388)</span>, Randomized Controlled Clinical Trial <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-v3-nciThesaurus.html">NCI Thesaurus</a>#C46079)</span>, Double Blind Study <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-v3-nciThesaurus.html">NCI Thesaurus</a>#C15228)</span>, Unequal Randomization <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-v3-nciThesaurus.html">NCI Thesaurus</a>#C142743)</span></p><p><b>focus</b>: Pharmacologic Substance <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-v3-nciThesaurus.html">NCI Thesaurus</a>#C1909)</span></p><p><b>condition</b>: Alopecia areata (disorder) <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="https://browser.ihtsdotools.org/">SNOMED CT</a>#68225006)</span></p><p><b>location</b>: Germany <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-ISO3166Part1.html">ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code</a>#DE)</span>, France <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-ISO3166Part1.html">ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code</a>#FR)</span></p><p><b>period</b>: 2018-03-01 --&gt; 2022-03-17</p><p><b>principalInvestigator</b>: <a href="https://simplifier.net/resolve?scope=de.basisprofil.r4@1.4.0&amp;canonical=http://fhir.org/packages/de.basisprofil.r4/Practitioner/example">Practitioner/example</a></p><p><b>site</b>: </p><ul><li><a href="https://simplifier.net/resolve?scope=de.basisprofil.r4@1.4.0&amp;canonical=http://fhir.org/packages/de.basisprofil.r4/Organization/Charite-dermatology">Organization/Charite-dermatology</a></li><li><a href="https://simplifier.net/resolve?scope=de.basisprofil.r4@1.4.0&amp;canonical=http://fhir.org/packages/de.basisprofil.r4/Organization/Sabouraud-Center">Organization/Sabouraud-Center</a></li><li><a href="https://simplifier.net/resolve?scope=de.basisprofil.r4@1.4.0&amp;canonical=http://fhir.org/packages/de.basisprofil.r4/Organization/Diagnostic-consulting-center-XXIV-Sofia">Organization/Diagnostic-consulting-center-XXIV-Sofia</a></li><li><a href="https://simplifier.net/resolve?scope=de.basisprofil.r4@1.4.0&amp;canonical=http://fhir.org/packages/de.basisprofil.r4/Organization/SC-Centrul-Medical-Sana-SRL">Organization/SC-Centrul-Medical-Sana-SRL</a></li></ul><blockquote><p><b>arm</b></p><p><b>name</b>: Experimental: LH-8 cutaneous solution</p><p><b>type</b>: Investigational Arm <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-v3-nciThesaurus.html">NCI Thesaurus</a>#C174266)</span></p><p><b>description</b>: LH-8 cutaneous solution (0.126 mL per spray) applied to the whole scalp</p></blockquote><blockquote><p><b>arm</b></p><p><b>name</b>: Placebo Comparator: Placebo cutaneous solution</p><p><b>type</b>: Control Arm <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-v3-nciThesaurus.html">NCI Thesaurus</a>#C174226)</span></p><p><b>description</b>: Placebo cutaneous solution (0.126 mL per spray) applied to the whole scalp</p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Relative change in scalp alopecia areata severity scores (SALT) from baseline value to be assessed after 24 weeks of treatment. [ Time Frame: 24 weeks treatment ] Visual assessment and global standardised scalp photographs for SALT evaluation.</p><p><b>type</b>: Primary <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-research-study-objective-type.html">ResearchStudyObjectiveType</a>#primary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Absolute change in SALT score from baseline at the end of 24 weeks' treatment period. [ Time Frame: 24 weeks treatment ]</p><p><b>type</b>: Secondary <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-research-study-objective-type.html">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Proportion of the responders, i.e. subjects achieving at least a 40% relative reduction in SALT score from baseline at the end of 24 weeks' treatment period. [ Time Frame: 24 weeks treatment ]</p><p><b>type</b>: Secondary <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-research-study-objective-type.html">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Adverse events [ Time Frame: 48 weeks ]</p><p><b>type</b>: Secondary <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-research-study-objective-type.html">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: General physical examination findings, including irritation of eyes and skin [ Time Frame: 24 weeks treatment ]</p><p><b>type</b>: Secondary <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-research-study-objective-type.html">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Visual assessment and global standardised scalp photographs for SALT evaluation. [ Time Frame: After 12 and 24 weeks treatment ]</p><p><b>type</b>: Secondary <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-research-study-objective-type.html">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Evaluation of duration of treatment effect in responders, measured as relative SALT score changes from Visit 3 (end of treatment) after 12 weeks (Visit 4) and 24 weeks (Visit 5) of treatment-free period. (Visual assessment and global standardised scalp photographs for SALT evaluation.)</p><p><b>type</b>: Secondary <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-research-study-objective-type.html">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Assessment of treatment effect on hair follicles in non-alopecic areas by quantifying the number of new alopecic areas. [ Time Frame: 24 weeks treatment ]</p><p><b>type</b>: Secondary <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-research-study-objective-type.html">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Assessment of the rate of spontaneous hair regrowth. [ Time Frame: For 6-12 months ]</p><p><b>type</b>: Secondary <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-research-study-objective-type.html">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Assessment of the rate of spontaneous hair regrowth in placebo treated subjects with alopecia areata active for 6-12 months compared to those with alopecia areata active for more than 12 months. (Visual assessment and global standardised scalp photographs for SALT evaluation).</p><p><b>type</b>: Secondary <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-research-study-objective-type.html">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Absolute and relative change from baseline in Children's Dermatology Life Quality Index (CDLQI) scores. [ Time Frame: 48 weeks ]</p><p><b>type</b>: Secondary <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-research-study-objective-type.html">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Change in percentage of subjects from baseline by the severity banding CDLQI scores. [ Time Frame: 48 weeks ]</p><p><b>type</b>: Secondary <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-research-study-objective-type.html">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Percentages of subjects by EuroQol Five Dimensions Youth Questionnaire (EQ-5D-Y) dimensions and levels at Visits 1-5. [ Time Frame: 48 weeks ]</p><p><b>type</b>: Secondary <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-research-study-objective-type.html">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Absolute and relative change of the EQ-Visual Analogue Scale (EQ-VAS) scores from baseline [ Time Frame: 48 weeks ]</p><p><b>type</b>: Secondary <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-research-study-objective-type.html">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Evaluation of the Paediatric Alopecia Areata Patient Benefit Index (PAAPBI) scores at Visits 1 to 5. [ Time Frame: 48 weeks ]</p><p><b>type</b>: Secondary <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.0.0/CodeSystem-research-study-objective-type.html">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote></div>
  </text>
  <identifier>
    <system value="http://clinicaltrials.gov"/>
    <value value="NCT03240627"/>
  </identifier>
  <title value="Double-blind, Vehicle-controlled, Randomised, Multi-centre Study to Evaluate the Efficacy and Safety of LH-8 Cutaneous Solution in Children and Adolescents With Moderate to Severe Scalp Alopecia Areata."/>
  <status value="completed"/>
  <primaryPurposeType>
    <coding>
      <system value="http://terminology.hl7.org/CodeSystem/research-study-prim-purp-type"/>
      <code value="treatment"/>
    </coding>
  </primaryPurposeType>
  <phase>
    <coding>
      <system value="http://terminology.hl7.org/CodeSystem/research-study-phase"/>
      <code value="phase-2-phase-3"/>
      <display value="Phase 2/Phase 3"/>
    </coding>
  </phase>
  <category>
    <coding>
      <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
      <code value="C98388"/>
      <display value="Interventional Study"/>
    </coding>
  </category>
  <category>
    <coding>
      <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
      <code value="C46079"/>
      <display value="Randomized Controlled Clinical Trial"/>
    </coding>
  </category>
  <category>
    <coding>
      <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
      <code value="C15228"/>
      <display value="Double Blind Study"/>
    </coding>
  </category>
  <category>
    <coding>
      <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
      <code value="C142743"/>
      <display value="Unequal Randomization"/>
    </coding>
  </category>
  <focus>
    <coding>
      <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
      <code value="C1909"/>
      <display value="Pharmacologic Substance"/>
    </coding>
  </focus>
  <condition>
    <coding>
      <system value="http://snomed.info/sct"/>
      <code value="68225006"/>
      <display value="Alopecia areata (disorder)"/>
    </coding>
  </condition>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <code value="DE"/>
      <display value="Germany"/>
    </coding>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <code value="FR"/>
      <display value="France"/>
    </coding>
  </location>
  <period>
    <start value="2018-03-01"/>
    <end value="2022-03-17"/>
  </period>
  <principalInvestigator>
    <reference value="Practitioner/example"/>
  </principalInvestigator>
  <site>
    <reference value="Organization/Charite-dermatology"/>
  </site>
  <site>
    <reference value="Organization/Sabouraud-Center"/>
  </site>
  <site>
    <reference value="Organization/Diagnostic-consulting-center-XXIV-Sofia"/>
  </site>
  <site>
    <reference value="Organization/SC-Centrul-Medical-Sana-SRL"/>
  </site>
  <arm>
    <name value="Experimental: LH-8 cutaneous solution"/>
    <type>
      <coding>
        <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
        <code value="C174266"/>
        <display value="Investigational Arm"/>
      </coding>
    </type>
    <description value="LH-8 cutaneous solution (0.126 mL per spray) applied to the whole scalp"/>
  </arm>
  <arm>
    <name value="Placebo Comparator: Placebo cutaneous solution"/>
    <type>
      <coding>
        <system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
        <code value="C174226"/>
        <display value="Control Arm"/>
      </coding>
    </type>
    <description value="Placebo cutaneous solution (0.126 mL per spray) applied to the whole scalp"/>
  </arm>
  <objective>
    <name value="Relative change in scalp alopecia areata severity scores (SALT) from baseline value to be assessed after 24 weeks of treatment. [ Time Frame: 24 weeks treatment ] Visual assessment and global standardised scalp photographs for SALT evaluation."/>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
        <code value="primary"/>
      </coding>
    </type>
  </objective>
  <objective>
    <name value="Absolute change in SALT score from baseline at the end of 24 weeks' treatment period. [ Time Frame: 24 weeks treatment ]"/>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
        <code value="secondary"/>
      </coding>
    </type>
  </objective>
  <objective>
    <name value="Proportion of the responders, i.e. subjects achieving at least a 40% relative reduction in SALT score from baseline at the end of 24 weeks' treatment period. [ Time Frame: 24 weeks treatment ]"/>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
        <code value="secondary"/>
      </coding>
    </type>
  </objective>
  <objective>
    <name value="Adverse events [ Time Frame: 48 weeks ]"/>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
        <code value="secondary"/>
      </coding>
    </type>
  </objective>
  <objective>
    <name value="General physical examination findings, including irritation of eyes and skin [ Time Frame: 24 weeks treatment ]"/>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
        <code value="secondary"/>
      </coding>
    </type>
  </objective>
  <objective>
    <name value="Visual assessment and global standardised scalp photographs for SALT evaluation. [ Time Frame: After 12 and 24 weeks treatment ]"/>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
        <code value="secondary"/>
      </coding>
    </type>
  </objective>
  <objective>
    <name value="Evaluation of duration of treatment effect in responders, measured as relative SALT score changes from Visit 3 (end of treatment) after 12 weeks (Visit 4) and 24 weeks (Visit 5) of treatment-free period. (Visual assessment and global standardised scalp photographs for SALT evaluation.)"/>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
        <code value="secondary"/>
      </coding>
    </type>
  </objective>
  <objective>
    <name value="Assessment of treatment effect on hair follicles in non-alopecic areas by quantifying the number of new alopecic areas. [ Time Frame: 24 weeks treatment ]"/>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
        <code value="secondary"/>
      </coding>
    </type>
  </objective>
  <objective>
    <name value="Assessment of the rate of spontaneous hair regrowth. [ Time Frame: For 6-12 months ]"/>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
        <code value="secondary"/>
      </coding>
    </type>
  </objective>
  <objective>
    <name value="Assessment of the rate of spontaneous hair regrowth in placebo treated subjects with alopecia areata active for 6-12 months compared to those with alopecia areata active for more than 12 months. (Visual assessment and global standardised scalp photographs for SALT evaluation)."/>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
        <code value="secondary"/>
      </coding>
    </type>
  </objective>
  <objective>
    <name value="Absolute and relative change from baseline in Children's Dermatology Life Quality Index (CDLQI) scores. [ Time Frame: 48 weeks ]"/>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
        <code value="secondary"/>
      </coding>
    </type>
  </objective>
  <objective>
    <name value="Change in percentage of subjects from baseline by the severity banding CDLQI scores. [ Time Frame: 48 weeks ]"/>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
        <code value="secondary"/>
      </coding>
    </type>
  </objective>
  <objective>
    <name value="Percentages of subjects by EuroQol Five Dimensions Youth Questionnaire (EQ-5D-Y) dimensions and levels at Visits 1-5. [ Time Frame: 48 weeks ]"/>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
        <code value="secondary"/>
      </coding>
    </type>
  </objective>
  <objective>
    <name value="Absolute and relative change of the EQ-Visual Analogue Scale (EQ-VAS) scores from baseline [ Time Frame: 48 weeks ]"/>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
        <code value="secondary"/>
      </coding>
    </type>
  </objective>
  <objective>
    <name value="Evaluation of the Paediatric Alopecia Areata Patient Benefit Index (PAAPBI) scores at Visits 1 to 5. [ Time Frame: 48 weeks ]"/>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/research-study-objective-type"/>
        <code value="secondary"/>
      </coding>
    </type>
  </objective>
</ResearchStudy>